Logo

Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Share this
Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Shots:

  • The companies collaborated to commercialize Bioeq's FYB201 (biosimilar referencing Lucentis) in the EU- Canada- Israel & New Zealand
  • Bioeq will be responsible for the development- registration- and supply of the biosimilar while Teva will be responsible for commercializing the product. The companies will share revenue from the commercialization of the biosimilar
  • The collaboration will expand Teva’s biosimilar portfolio & strengthen the development of biosimilar drugs for highly regulated countries. Additionally- Bioeq has in licensed the exclusive global commercialization rights to FYB201 from Formycon

  | Ref: Teva | Image: Rasayanika

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions